Bluejay Diagnostics (BJDX) Consolidated Net Income (2022 - 2023)
Bluejay Diagnostics (BJDX) has disclosed Consolidated Net Income for 2 consecutive years, with -$2.4 million as the latest value for Q4 2023.
- Quarterly Consolidated Net Income rose 2.73% to -$2.4 million in Q4 2023 from the year-ago period, while the trailing twelve-month figure was -$10.3 million through Dec 2023, down 10.66% year-over-year, with the annual reading at -$6.9 million for FY2025, 12.62% up from the prior year.
- Consolidated Net Income hit -$2.4 million in Q4 2023 for Bluejay Diagnostics, down from -$2.3 million in the prior quarter.
- In the past five years, Consolidated Net Income ranged from a high of -$2.0 million in Q2 2022 to a low of -$2.9 million in Q2 2023.